menu
    • menu

    Company profile for TCR2 Therapeutics

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We have built a robust pipeline of TRuC-T cell product candidates for solid and hematologic cancers. The versatility of our platform is highlighted by the multiple programs and multiple formats of the product candidates in our pipeline. In preclinical studies with TRuC-T cell product candidates, we have shown better anti-tumor activity, longer persistence, and lower cytokine release compared to CAR-T cells bearing the same...
    We have built a robust pipeline of TRuC-T cell product candidates for solid and hematologic cancers. The versatility of our platform is highlighted by the multiple programs and multiple formats of the product candidates in our pipeline. In preclinical studies with TRuC-T cell product candidates, we have shown better anti-tumor activity, longer persistence, and lower cytokine release compared to CAR-T cells bearing the same tumor antigen binding domains. The FDA cleared the IND for TC-210, our lead candidate, in January 2019, and we plan to initiate TC-210’s Phase 1/2 clinical trial in early 2019.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TCR2 TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    100 Binney Street, Suite 710 Cambridge, MA 02142
    Telephone
    Telephone
    617.949.5200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tcr2.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    08 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/08/2663841/0/en/TCR-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    08 May 2023
    Share Share
    TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    03 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/03/2640162/0/en/TCR-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    03 Apr 2023
    Share Share
    TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results
    TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results

    23 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/23/2632946/0/en/TCR-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    23 Mar 2023
    Share Share
    Adaptimmune & TCR² Announce Combination to Create Cell Therapy Company
    Adaptimmune & TCR² Announce Combination to Create Cell Therapy Company

    06 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/06/2620800/0/en/Adaptimmune-and-TCR-Therapeutics-Announce-Strategic-Combination-to-Create-a-Preeminent-Cell-Therapy-Company-for-Solid-Tumors.html

    GLOBENEWSWIRE
    06 Mar 2023
    Share Share
    TCR2 Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
    TCR2 Therapeutics to Present at SVB Securities Global Biopharma Conference 2023

    08 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/08/2603758/0/en/TCR-Therapeutics-to-Present-at-SVB-Securities-Global-Biopharma-Conference-2023.html

    GLOBENEWSWIRE
    08 Feb 2023
    Share Share
    TCR² first began layoffs back in August
    TCR² first began layoffs back in August

    13 Jan 2023

    // Max Bayer FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/scoop-tcr2-therapeutics-just-laid-40-its-staff-its-second-round-cuts-less-six-months

    Max Bayer FIERCE BIOTECH
    13 Jan 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search